Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial

• DOI: 10.1111/dom.15464
• Publication Date: 2024-01-19T09:08:58Z
• Authors: Liv Vernstrøm; Søren Gullaksen; Steffen S. Sørensen; Kristian L. Funck; Esben Laugesen; Per L. Poulsen
• Keywords: Blood Glucose; Diabetes Mellitus, Type 2/complications; Blood Glucose Self-Monitoring; Benzhydryl Compounds/adverse effects; macrovascular disease; Glucagon-Like Peptides; Pulse Wave Analysis; glucagon-like peptide-1 analogue; sodium–glucose cotransporter 2 inhibitor; Hypoglycemic Agents/adverse effects; Treatment Outcome; Double-Blind Method; Glucosides; Creatinine; Albumins; drug mechanism; Humans; continuous glucose monitoring; type 2 diabetes

AbstractAimDespite the increasing use of combination treatment with sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide‐1 receptor agonists, data are limited on the effects of combination treatment on markers of cardiovascular disease. This study aimed to investigate the effect of empagliflozin, semaglutide, and their combination on vascular function.Materials and MethodsIn total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination. The study had two co‐primary outcomes: change in arterial stiffness and kidney oxygenation. This paper reports on arterial stiffness assessed as carotid‐femoral pulse wave velocity. Secondary outcomes included 24‐h blood pressure (BP), 24‐h central BP, urinary albumin to creatinine ratio and glycaemic control assessed by both continuous glucose monitoring and glycated haemoglobin.ResultsThe carotid‐femoral pulse wave velocity did not change significantly in any of the groups compared with placebo. Twenty‐four‐hour systolic BP was reduced by 10 mmHg (95% CI 6–14), p < .001 in the combination group, significantly superior to both placebo and monotherapy (p < .05). Combination treatment increased glycaemic time in range from 72% at baseline to 91% at week 32, p < .001, without increasing time below range. The urinary albumin to creatinine ratio decreased by 36% (95% CI 4–57), p = .03 in the combination group compared with placebo.ConclusionsEmpagliflozin, semaglutide, or their combination did not reduce arterial stiffness. Combination treatment showed a substantial and clinically important reduction in 24‐h systolic BP compared with either treatment alone. Combination treatment increased glycaemic time in range without increasing the risk of hypoglycaemia.